Is P3 Health Partners, Inc. overvalued or undervalued?

As of 9 February 2022, the valuation grade for P3 Health Partners, Inc. has moved from does not qualify to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 0.75, an EV to EBITDA of -0.81, and a ROE of -509.38%. In comparison, peers like TaskUs, Inc. show a much healthier P/E ratio of 27.32 and EV to EBITDA of 10.15, while Information Services Group, Inc. has a P/E of 22.59 and EV to EBITDA of 12.80, highlighting the stark contrast in financial health.
The stock has underperformed significantly against the S&P 500, with a year-to-date return of -32.68% compared to the benchmark's 12.22%. This underperformance reinforces the notion that P3 Health Partners, Inc. is currently overvalued in the market.